Teva targets $6–7 billion innovative medicines revenue by 2030
At its first R&D Day, Teva laid out financial goals through 2030, covering innovative revenue, free cash flow and gross margins.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Teva Pharmaceutical Industries said on Wednesday, ahead of its first-ever R&D Day, that it plans to bring revenue from its innovative medicines portfolio to $6–7 billion by 2030, according to Seeking Alpha. Since its Pivot to Growth strategy began in 2023, the company has more than doubled innovative medicines revenue. CEO Richard Francis said Teva has also returned to investment grade and built a pipeline with more than $10 billion in peak sales potential.
The company aims to launch one innovative medicine a year over the next five years. It projects sales of Austedo, Ajovy and Uzedy to grow by more than 125% by the end of this year. For 2026–2030, Teva expects mid-single-digit revenue growth, over $3.5 billion in free cash flow by the end of the decade, and gross margins above 75% on innovative products.
why it matters
For the market, these are mainly corporate targets that investors will check against actual results. Teva's shift from generics toward innovative drugs changes its margin mix, so the performance of Austedo, Ajovy and Uzedy will be the key indicator to watch.
market impact
Teva: its own revenue and margin targets serve as a benchmark for investors in the company
tags
instruments
sources
- Teva outlines 2030 targets ahead of R&D Day event — Seeking Alpha, 11 November 2026 at 13:15 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗